The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.

The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.

The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.

The companies will initially develop an AI-based test to select patients with CDH17-expressing gastrointestinal cancers for Arbele's Phase I drug trial.

Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to ...

Researchers hope DeepGEM can expedite targeted treatment for lung cancer patients who can't access standard genomic testing.

In a report, a working group cautioned that the program must lessen its reliance on congressional appropriations or risk ...

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.

NEW YORK – The US Food and Drug Administration on Wednesday approved AstraZeneca's Tagrisso (osimertinib) for certain patients with stage III EGFR-mutated non-small cell lung cancer. The EGFR ...

NEW YORK – ReCode Therapeutics on Thursday said it has treated the first cystic fibrosis patient with its inhaled messenger RNA (mRNA) therapy within a Phase Ib trial. Investigators will assess the ...